Tempest Therapeutics, Inc. (TPST)

Over the past six months, Tempest Therapeutics' stock price has been volatile. Key events include Q3 2025 earnings exceeding expectations, followed by a stock price decline, an $8.35 million registered direct offering, a record date for a warrant dividend distribution, an upgrade by H.C. Wainwright & Co., and the closing of a strategic acquisition of CAR-T assets with Matt Angel's appointment as CEO. The price target was increased by 22.22% to $11.22.

The demand for Tempest Therapeutics' products and services is not subject to typical seasonal fluctuations. Demand is driven by the need for effective cancer treatments and the progression of clinical trials and regulatory approvals.

Tempest Therapeutics, Inc. (TPST) is a clinical-stage biotechnology company focused on discovering and developing small molecule therapeutics for cancer treatment. Their core business involves advancing drug candidates through preclinical and clinical development, targeting mechanisms that directly kill tumor cells and activate tumor-specific immunity. Key product candidates include Amezalpat (TPST-1120), an oral small molecule selective antagonist of PPARα being developed for liver cancer, and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, intended for treating various cancers.

Tempest Therapeutics, Inc. is headquartered in Brisbane, California, United States, and has initiated early-phase clinical studies in North America and Europe.

Tempest Therapeutics' brand reputation reflects promising scientific advancements and financial challenges. Positive updates from the MORPHEUS-Liver study and the NCI funding for the TPST-1495 Phase 2 trial have bolstered the company's outlook. However, concerns exist regarding financial stability and development costs, leading to a strategic review and a significant stock price decline.

Approximately 22.0% of Tempest Therapeutics' outstanding shares are held by institutional holders, while 0.09% are owned by insiders, and 77.91% by the general public. Another source indicates that approximately 3.92% of the company's stock is owned by Institutional Investors, 3.43% by Insiders, and 92.65% by Public Companies and Individual Investors. Major institutional owners include Vanguard Group Inc., Versant Venture Management, LLC, and BlackRock, Inc. Brad Bolzon owns the most shares of Tempest Therapeutics.